Does the media refer more to AXSM or MBX?

In the previous week, Axsome Therapeutics had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Axsome Therapeutics and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.24 beat Axsome Therapeutics' score of 0.01 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRNX or MBX?

In the previous week, MBX Biosciences had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for MBX Biosciences and 1 mentions for Crinetics Pharmaceuticals. MBX Biosciences' average media sentiment score of 0.24 beat Crinetics Pharmaceuticals' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, BLTE or MBX?

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is BLTE or MBX more profitable?

Belite Bio's return on equity of -11.84% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% MBX Biosciences N/A -26.02% -24.94%

Does the media favor BLTE or MBX?

In the previous week, Belite Bio and Belite Bio both had 5 articles in the media. MBX Biosciences' average media sentiment score of 0.24 beat Belite Bio's score of 0.20 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LNTH or MBX more profitable?

Lantheus has a net margin of 17.69% compared to MBX Biosciences' net margin of 0.00%. Lantheus' return on equity of 28.10% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% MBX Biosciences N/A -26.02% -24.94%

Does the media favor LNTH or MBX?

In the previous week, Lantheus had 6 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Lantheus and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.24 beat Lantheus' score of 0.23 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

MBX Biosciences (MBX) Competitors

$58.51 +1.96 (+3.47%)

Closing price 04:00 PM Eastern

Extended Trading

$58.54 +0.03 (+0.05%)

As of 07:30 PM Eastern

Compare

MBX vs. RDY, AXSM, CRNX, BLTE, and LNTH

Should you buy MBX Biosciences stock or one of its competitors? MBX Biosciences's main competitors and comparable companies include Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

MBX Biosciences (NASDAQ:MBX) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MBX Biosciences' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

MBX Biosciences has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Dr. Reddy's Laboratories	$3.58B	2.83	$456M	$0.44	27.63

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MBX Biosciences presently has a consensus target price of $83.89, suggesting a potential upside of 42.47%. Dr. Reddy's Laboratories has a consensus target price of $1,450.00, suggesting a potential upside of 11,829.25%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, MBX Biosciences had 5 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for MBX Biosciences and 0 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 0.24 beat Dr. Reddy's Laboratories' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
MBX Biosciences	Neutral
Dr. Reddy's Laboratories	Neutral

Summary

Dr. Reddy's Laboratories beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

MBX Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	14.52	-$183.17M	-$3.75	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

MBX Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. MBX Biosciences' return on equity of -26.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
MBX Biosciences	N/A	-26.02%	-24.94%

Axsome Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Axsome Therapeutics presently has a consensus target price of $275.84, suggesting a potential upside of 55.87%. MBX Biosciences has a consensus target price of $83.89, suggesting a potential upside of 42.47%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Axsome Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Axsome Therapeutics had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Axsome Therapeutics and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.24 beat Axsome Therapeutics' score of 0.01 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MBX Biosciences beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

MBX Biosciences has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. MBX Biosciences' return on equity of -26.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
MBX Biosciences	N/A	-26.02%	-24.94%

MBX Biosciences has lower revenue, but higher earnings than Crinetics Pharmaceuticals. MBX Biosciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, MBX Biosciences had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for MBX Biosciences and 1 mentions for Crinetics Pharmaceuticals. MBX Biosciences' average media sentiment score of 0.24 beat Crinetics Pharmaceuticals' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crinetics Pharmaceuticals presently has a consensus target price of $83.44, indicating a potential downside of 1.77%. MBX Biosciences has a consensus target price of $83.89, indicating a potential upside of 42.47%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe MBX Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Crinetics Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Summary

MBX Biosciences beats Crinetics Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Belite Bio's return on equity of -11.84% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
MBX Biosciences	N/A	-26.02%	-24.94%

In the previous week, Belite Bio and Belite Bio both had 5 articles in the media. MBX Biosciences' average media sentiment score of 0.24 beat Belite Bio's score of 0.20 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

Belite Bio currently has a consensus price target of $218.73, suggesting a potential upside of 33.60%. MBX Biosciences has a consensus price target of $83.89, suggesting a potential upside of 42.47%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

MBX Biosciences beats Belite Bio on 9 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Lantheus has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.12
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Lantheus presently has a consensus price target of $108.11, suggesting a potential upside of 8.26%. MBX Biosciences has a consensus price target of $83.89, suggesting a potential upside of 42.47%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Lantheus had 6 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Lantheus and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.24 beat Lantheus' score of 0.23 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to MBX Biosciences' net margin of 0.00%. Lantheus' return on equity of 28.10% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
MBX Biosciences	N/A	-26.02%	-24.94%

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lantheus beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.72B	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.76%
P/E Ratio	-24.28	794.62	273.67	26.04
Price / Sales	N/A	755.06	611.82	91.49
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	7.12	10.46	10.92	6.30
Net Income	-$86.97M	$2.83B	$3.50B	$361.43M
7 Day Performance	9.10%	-1.65%	-2.11%	-1.67%
1 Month Performance	-3.91%	-5.77%	-6.34%	-3.94%
1 Year Performance	249.31%	-3.80%	8.81%	2.77%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	2.6495 of 5 stars	$58.51 +3.5%	$83.89 +43.4%	+215.9%	$2.72B	N/A	N/A	63	Analyst Forecast
RDY Dr. Reddy's Laboratories	3.458 of 5 stars	$12.26 -0.3%	N/A	-13.7%	$10.22B	$331.19B	27.87	27,527	Analyst Upgrade
AXSM Axsome Therapeutics	3.4451 of 5 stars	$195.09 -0.5%	$271.65 +39.2%	+53.6%	$10.22B	$776.57M	N/A	925	Analyst Forecast
CRNX Crinetics Pharmaceuticals	0.9804 of 5 stars	$84.95 flat	$83.90 -1.2%	N/A	$9.01B	$7.70M	N/A	210
BLTE Belite Bio	3.3351 of 5 stars	$167.33 -1.2%	$218.73 +30.7%	+121.7%	$6.74B	N/A	N/A	41

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. RDY, AXSM, CRNX, BLTE, and LNTH

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does MBX Biosciences compare to Axsome Therapeutics?

Summary

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Summary

How does MBX Biosciences compare to Belite Bio?

Summary

How does MBX Biosciences compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. RDY, AXSM, CRNX, BLTE, and LNTH

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Is MBX or RDY more profitable?

Which has more risk and volatility, MBX or RDY?

Which has higher valuation and earnings, MBX or RDY?

Do insiders & institutionals have more ownership in MBX or RDY?

Do analysts rate MBX or RDY?

Does the media favor MBX or RDY?

Summary

How does MBX Biosciences compare to Axsome Therapeutics?

Which has better earnings & valuation, AXSM or MBX?

Is AXSM or MBX more profitable?

Which has more volatility & risk, AXSM or MBX?

Do institutionals and insiders hold more shares of AXSM or MBX?

Do analysts prefer AXSM or MBX?

Does the media refer more to AXSM or MBX?

Summary

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Is CRNX or MBX more profitable?

Which has better valuation & earnings, CRNX or MBX?

Do institutionals and insiders have more ownership in CRNX or MBX?

Does the media refer more to CRNX or MBX?

Do analysts rate CRNX or MBX?

Which has more risk & volatility, CRNX or MBX?

Summary

How does MBX Biosciences compare to Belite Bio?

Is BLTE or MBX more profitable?

Does the media favor BLTE or MBX?

Do institutionals and insiders hold more shares of BLTE or MBX?

Which has stronger valuation and earnings, BLTE or MBX?

Which has more volatility and risk, BLTE or MBX?

Do analysts recommend BLTE or MBX?

Summary

How does MBX Biosciences compare to Lantheus?

Which has better valuation & earnings, LNTH or MBX?

Do analysts prefer LNTH or MBX?

Does the media favor LNTH or MBX?

Which has more volatility and risk, LNTH or MBX?

Is LNTH or MBX more profitable?

Do insiders and institutionals hold more shares of LNTH or MBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools